Ambulatory monitoring for heart failure patient: comparison between home monitoring and usual care or daily clinics and usual care
|
|
- Arthur Carter
- 8 years ago
- Views:
Transcription
1 FACULTY OF MEDICINE UNIVERSITY OF PORTO Department of Biostatistics and Medical Informatics Introduction to Medicine 2005/2006 Ambulatory monitoring for heart failure patient: comparison between home monitoring and usual care or daily clinics and usual care Barros J (med05219@med.up.pt), Barros JM (med05218@med.up.pt), Coutinho S (med05097@med.up.pt), Fernandes C (med05174@med.up.pt), Ferreira Mª (med05025@med.up.pt), Gomes J (med05239@med.up.pt), Lima J (med05216@med.up.pt), Neves J (med05221@med.up.pt), Puga F (med05242@med.up.pt), Rocha J (med05215@med.up.pt), Silva J (med05217@med.up.pt) 2006 Head teacher: Prof. Dr. Altamiro da Costa Pereira Guiding teacher: Dr. Filipa Almeida (filipa.almeida@med.up.pt) Abstract Introduction: Heart failure (HF) afflicts several people all over the world so it extremely important to improve treatment management strategies. Heart failure patients can be supervised by an ambulatory system in alternative to the standard care. Aim: Comparison between home monitoring and usual care or daily clinics and usual care, in order to find out if there are additional advantages in these two types of ambulatory monitoring in comparison with usual care. Methods: A literature search was performed including randomized clinical trials using the databases MEDLINE and Cochrane library, from the earliest article available until the March Results: In relation to mortality, home monitoring comparing with the standard care revealed a RR (relative risk) reduction for the home treatment of 38% (RR 0,62 [IC95% 0,46;0,84]). With the study of the association between daily clinics and usual care as far as mortality was concerned RR reduction for daily clinics of 45% was obtained (RR 0,55 [IC95% 0,41;0,75]). These results were statistically significant. Concerning the readmissions the comparison between home monitoring and standard care revealed a RR of 0, 81 (IC95% 0,34;1,96). The results were not statistically significant. The comparison between daily clinics and usual care concerning the readmission rate, demonstrate a RR reduction in readmission for daily clinics patients of 33% (RR 0,67 [IC95% 0,56;0,81])for those which the follow up time was less than one year. The results for the patients followed up for one year or more didn t have statistically significant results. Conclusion: A statistical significant reduction was found in mortality in the group of patients submitted to home monitoring or daily clinics monitoring when compared to standard care. Concerning the hospital readmission rate, there was a significant reduction in the intervention group submitted to daily clinics monitoring when the follow up was less than a year. No statistical difference was found in patients submitted to daily clinics monitoring followed for more than a year or for patients submitted to home monitoring. Studies comparing daily clinics with home monitoring are needed to establish what is the best home treatment for chronic heart failure patients. Keywords: Chronic heart failure; Home monitoring; Telemonitoring; Outpatient management, Heart failure clinics 1
2 Introduction Heart failure (HF) afflicts several people all over the world so it extremely important to improve treatment management strategies. Heart or cardiac failure (HF) is the pathophysiologic state in which the heart is enable to pump blood at a rate commensurate with the requirements of the metabolizing tissues [1]. It s a complex clinical syndrome that can result from any structural or functional cardiac disorders that impairs the ability of the ventricle to fill with or eject blood [2]. Although this is a very restricted concept as there are plenty definitions and none reveals completely its multidynamic character and only selective features of this complex syndrome are highlighted. None is entirely satisfactory [3]. This pathology may result of an aggravation of other diseases or conditions that interfere with the well functioning of cardiac muscle. The effective symptoms and signs, like breathlessness, fatigue and ankle swelling, seem to be common to other diseases making the clinical diagnosis difficult, especially in women, elderly and obese. The most common aetiologies are the coronary artery disease, high blood pressure (hypertension), valve abnormalities, cardiomyopathy (heart muscle disease- Dilated/ Hypertrophic/ Restrictive), rhythm disturbances and idiopathic [4]. Concerning the prevalence and incidence, previous studies concluded that 4,9 million persons in USA are being treated for heart failure [5] and 10% of patients older than 75 years have heart failure. Actually, this pathology is the most common cause of hospitalization due to cardiovascular disease in patients over 65 years of age [6]. The number of HF deaths has increased steadily despite advances in treatment [7] as a consequence of the extraordinary number of new cases diagnosed each year ( [6]). Thus, the aim of the HF treatment is to control the disease s progression, decreasing the worsening of symptoms, with the crucial purpose of improving patients quality of life and to avoid re-admissions, as its most common forms cannot be completely eliminated. The prevention of heart failure should always be a primary objective [8]. There are a lot of drugs that can be used in the treatment of HF, such as: pharmacological therapy like ACE- inhibitors, diuretics, beta- adrenoceptor antagonists, vasodilator agents and positive inotropic agents and also non-pharmacological management, devices and surgery [3]. As a result, monitoring allows the control of variables (blood pressure, pulse and oximetry) measured by patients at home or in a health care system. Ambulatory 2
3 monitoring can provide diagnostic information which is then interpreted by expertise in order to assist treatment decisions. Most patients have multiple medical, social and behavioural challenges, and effective care requires a multidisciplinary system [9]. So, there are a lot of HF diseasemanagement programs to provide Intensive patient education, try to encourage patients to be more aggressive in their care, to keep them in a close supervision (close monitoring), to carefully review the medication and others. So, we proposed ourselves to perform a systematic review based in clinical trials with the objective to establish the comparison between home monitoring and usual care or daily clinics and usual care, in order to find out if there are additional advantages in these two types of ambulatory monitoring in comparison with usual care. Methods I. Bibliographic research A systematic review including randomized clinical trials was made using the databases MEDLINE and Cochrane library, from the earliest article available until the March Two queries were used: Pubmed s query ("Heart Failure, Congestive"[MeSH] OR "chronic heart failure" OR "heart insufficiency" OR "cardiac insufficiency" OR cardiac failure AND "Monitoring, Ambulatory"[MeSH] OR "home monitoring" OR "self monitoring" OR Telemedicine"[MeSH] OR telemonitoring OR home care OR outpatient management OR heart failure clinics OR "Outpatient Clinics, Hospital"[MeSH] OR "Self Care"[MeSH] NOT letter OR review OR editorial OR meta-analysis OR "Heart-Assist Devices"[MeSH]) and Cochrane s query (Heart Failure, Congestive OR chronic heart failure OR heart insufficiency OR cardiac insufficiency OR cardiac failure AND Monitoring, Ambulatory OR home monitoring OR self monitoring OR Telemedicine OR telemonitoring OR home care OR outpatient management OR heart failure clinics OR Outpatient Clinics, Hospital OR Self Care). The study was limited to humans and a total of 831 Articles (PubMed) and 54 Articles (Cochrane) articles were obtained. II. Systematic review of the studies A group of inclusion and exclusion criteria were defined previously. With the 3
4 application of these criteria, on the final 12 articles were considered as valid. Initially, the articles we obtained were divided on 3 reviewer s groups, both containing 3 elements; each one read the articles of the group. To be included/excluded at least two reviewers s had to agree. (see articles selection flowchart below). a) Exclusion criteria Studies that did not evaluate the advantages of ambulatory or clinical monitoring were rejected, seeing as its acceptance would disobey to the primary aim inherent to this systematic revision. Also, the studies that didn t mention the methods used and the results were ignored because with them it wouldn t be possible do a systematic review. The articles that just presented results about costs were ignored as fine the studies that discussed clinical cases, drugs specific treatment or other factors influence. Articles comparing ambulatory and hospital monitoring were discarded, too. These were about other kinds of monitoring, reason by which they couldn t be considered in this systematic review. The studies that discuss ventricular therapeutics or data acquisition were also abandoned. Some articles were concerning supportive-educative intervention and technologies in improving heart failure-related self-care behaviour. These ones weren t accepted because of their outlying. At last, the articles not written in Portuguese, English, French or Spanish weren t read for the reason that it was impossible to realize their meaning. After the exclusion phase we obtained 125 Articles (Pubmed) and 13 Articles (Cochrane). b) Inclusion criteria The first inclusion criterion was choosing clinical trials of patients with heart failure using ambulatory monitoring. Studies that compared home with usual monitoring or clinical with usual monitoring were included because of their intimate relation and great importance to this systematic review. Studies about blood pressure, heart rate and oximetry monitoring were of a great meaning for the work once they gave a lot of precious information about the subject, so they were included. Those which mention the quality of life of population were included, once this parameter has an enormous value. Related articles were also searched in order to obtain all possible articles about our subject. 4
5 This inclusion phase resulted in 12 articles, 7 clinical trials comparing home monitoring with standard care and 5 daily clinics with usual care. c) Concordance analysis It was performed a Cohen Kappa (1960) and a SPSS inter-reviews reproductability tests, in the exclusion and inclusion phases. The concordance between the different reviewers of the three groups was evaluated. III. Data extraction and relevant criteria We gave attention to the baseline studies characteristics like age, sex, weight, blood pressure, their quality of life, and also mean time and type of intervention. Special attention was given to mortality and readmission rates, in each group. We defined the number of patients and the primary endpoints, too (see Table 1 below). So, we obtained the articles concerning some important quality criteria, such as the type of study (we only considered clinical trials to elaborate the meta-analysis) and the type of intervention was also a relevant point. The articles that didn t mention the methods used or didn t have the results and conclusions were discarded. The endpoints of each article were also analyzed in order to obtain the articles that evaluated important issues such as mortality and readmission rates and also the quality of life. Finally we extracted the outcomes to make sure that they were related to our study. IV. Data base creation Data related to the chosen articles were introduced on an electronic database, through SPSS 12.0 for Windows V. Statistical analysis All the analysis were conducted according to the intention-to-treat principle. Meta-analysis After verification if it was possible to perform a meta-analysis, we utilized the software named Review Manager (RevMan 4.2) where we calculated the relative 5
6 risk (RR) random and 95% confidence intervals of the variables that we thought to be important for analysis, such as mortality and readmission rates. We also applied heterogeneity tests, in order to evaluate the validate of generalizations. Statistical significance was determined if the null hypothesis could be rejected at the P< 0,05 level. Results The twelve studies included a total population of 2513 (1133 in control and 1380 in the intervention group). Concerning the baseline characteristics, the men rate in global population was 70%, particularly in control group was 70% (SD: 14%; m: 41%; M: 84%) and the men rate in intervention group 69% (SD: 17%; m: 32%; M: 93%).The mean age of population was 68 years. The follow up time was 341 days. These two populations (control and intervention groups) were homogeneous concerning gender, age and heart failure degree (NYHA). According to our primary endpoints, hospital readmission and global cardiac mortality we obtained the following results: mortality rate in intervention group was 14% and in control group was 30%. The readmission rate in intervention group was 32% and the readmission rate of control group was higher (59%). What concerns about our secondary endpoint, the quality of patients life, 4 articles did not study it; 3 articles didn t have significant differences between the intervention and the control group and 5 articles described a better quality of life in the intervention group. On one hand, relating to articles that refer to home monitoring against usual care, from a total of 1405 patients followed up during a mean of 382 days we extracted results about the primary endpoints. The readmission rate in control group was 70% in opposition to 33% in intervention group. Moreover, the control group revealed a mortality of 38% while the mortality rate in intervention group was 18%. On the other hand, the 1108 patients that were evaluated in the comparative study about daily clinics with usual care had a mean follow up time of 285 days. The readmission rate in control group was 50% in opposition to the 31% readmission rate in other group. In addiction, mortality rate in control group was 18% and the mortality rate in second group just 9%. We executed a meta-analysis in order to compare home treatment and daily clinics, both with usual care concerning the primary endpoints defined. First, we divided 6
7 the articles in two groups, the first one included patients that were followed up for a period less than one year and the second one those that had a follow up time of one year or more. In relation to mortality, home monitoring comparing with the standard care revealed for the first group, home monitoring had a 26% RR reduction (RR 0,74 [IC95% 0,41;01,32]) than usual care and for the second one, the reduction in the RR (0,58 [IC95% 0,41;0,83]) for home monitoring was higher (42% reduction). The heterogeneity test showed that both populations were homogeneous (0% heterogeneity). Globally, the study favoured the home monitoring taking into account that the RR (relative risk) reduction was 38% (RR 0,62 [IC95% 0,46;0,84]). The results were statistically significant. (see figure 2 below) With the study of the association between daily clinics and usual care as far as mortality was concerned we obtained the following results: When we studied the relationship between daily clinics and usual care as far as mortality was concerned we obtained the following results: for the group followed up for less than 1 year there was a reduction of 33% in mortality for those patients that attended daily clinics comparing with the standard care (RR 0,67 [IC95% 0,47;0,97]). This population had 0% of heterogeneity. The second group had a 62% reduction of the RR (0,38 [IC95% 0,19;0,80]) for daily clinics and the heterogeneity revealed 65,7%. In total, the RR reduction for daily clinics was 45% (RR 0,55 [IC95% 0,41;0,75])and these results were also statistically significant. Concerning the readmissions we evaluated the home monitoring in comparison with standard care. In this study we were only able to collect two articles and so we were not able to divide in accordance to the scheduled follow-up time. The RR achieved was 0, 81 (IC95% 0,34;1,96). However the results were not statistically significant and the heterogeneity test was 97,7% and so no relevant conclusions were obtained. The comparison between daily clinics and usual care concerning the readmission rate, demonstrate a RR reduction in readmission for daily clinics patients of 33% (RR 0,67 [IC95% 0,56;0,81])for those which the follow up time was less than one year. The population was homogeneous (0% on the heterogeneity test). On the second group supervised, the RR reduction in readmission rates for patients attended at daily clinics was 63% (RR 0,37 [IC95% 0,09;1,54]). Nevertheless the heterogeneity test presented a high result (96%). we were only able to obtain statistically significant results for the population which was evaluated for a period of less than one year. We noticed with the inter-reviewers reproductability tests, that the total mean 7
8 result comparing the reviewers with the final decision was 0,758 which revealed concordance. Discussion and Conclusion During this work there were several restrictions that probably influenced the final results and conclusions. One of it was the difficulty in the definition of the query. Seven different queries were constructed with the purpose of integrate the most possible articles related to the theme of the work. Even though, and as other limitation, the number of articles included was reduced. Potentially, more articles could be incorporated, but some of them had a restricted access. From those, which were selected and found, other problems emerged on the extraction of raw data from the clinical trials. As for the primary endpoint of mortality a statistical significant reduction was found in the group of patients submitted to home monitoring or daily clinics monitoring when compared to standard care. Concerning the hospital readmission rate, there was a significant reduction in the intervention group submitted to daily clinics monitoring when the follow up was less than a year. No statistical difference was found in patients submitted to daily clinics monitoring followed for more than a year or for patients submitted to home monitoring. In the last case only two articles were collected, with a short population which may have contributed to the non significant results and no relevant conclusions extracted. The present study should be repeated, with a higher population, to confirm the results obtained and achieve others. Quality of life of patients with heart failure was our secondary endpoint of this work, although this is a difficult goal to measure/evaluate as not all articles mentioned it. Within every articles acquired, eight studied it, five of them described a better quality of life in the intervention group; the other three articles didn t have significant differences between the intervention and the control groups. The home monitoring or the daily clinics monitoring of such patients is extremely time and resources consuming [21]. So, more studies need to be performed in order to evaluate not only the efficacy of these two types of ambulatory monitoring but also with reference to the costs. Other point to consider is about improving different methods of patients management out of hospital, more economical and awarded of their financial possibilities and interests. These pioneering forms of care must be regarded as a mixture of advantages, for patients, improving their wellbeing and comfort, and to the hospitals, which have several benefits, like the reduced mortality 8
9 and better quality of life supported to their patients and also the money saved with the low percentage of readmissions. To confirm the results achieved, it is important to perform more studies evaluating these and other relevant endpoints, especially studies that establish the direct comparison between home monitoring and daily clinics. As a result, the best ambulatory treatment for chronic heart failure patients will be inferred. A three group study (these two types of ambulatory monitoring and standard care) is also important to be performed. Acknowledgments To doctor Altamiro Costa Pereira for his constructive and hopeful critics witch helped a lot during the work. To doctor Filipa Almeida, for the orientation, witch was crucial during all the work. Finally, to Dr. Luís Azevedo for the instructions about meta-analysis. References [1] Braunwald, et al. A textbook of Cardiovascular Medicine. Elsevier Saunders, 7th Ed, [2] Hunt S et al. ACC/AHA 2005 Guidiline for the Diagnosis and MAnagement of CHF in the adult. JACC 2005; 38: [3] Swedberg K et al. Guidelines for the diagnosis and treatment of Chronic Heart Failure. Eur. Heart J 2005; 26: [4] Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure survey programmea survey on the quality of care among patients with heart failure in Europe. Part 1: patients characteristics and diagnosis. Eur Heart J 2003; 24: [5] Ho K et al. The epidemiology of heart failure: the Framingham Study. JACC 1993; 22: 6-21 [6] Louis A et al. A systematic review of telemonitoring for the management of heart failure. Eur J Heart Failure 2003; 5: [7] American Heart Association. Heart disease and stroke statistics: 2005 update. Dallas; American Heart Association 9
10 [8] Wilhelmsen L, Rosengren A, Eriksson H et al. Heart failure in the general population of men-morbidity, risk factors and prognosis. J Intern Med 2001; 249: [9] Rich M et al. A multipledisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. NEJM 1995; 333: [10] Ducharme A, Doyon O, et al. Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial. CMAJ 2005; 173(1): [11] Cleland JG, Louis AA, et al. Noninvasive home telemonitoring for patiets with heart failure at high risk of recurrent admission and death. J Am Coll Cardiol 2005 ; vol. 45, No. 10. [12] Thompson DR, Roebuck A, et al. Effects of a nurse-led, clinic and home-based intervention on recurrent hospital use in chronic heart failure. Eur J Heart Fail 2005.; 7: [13] Atienza F, Anguita M, et al. Multicenter randomized trial of a comprehensive hospital discharge and outpatient heart failure management program. Eur J Heart Fail 2004; 6: [14] Goldberg, et al. Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: The Weight Monitoring in Heart Failure (WHARF) trial. Am Heart J 2003; vol. 146, No. 4. [15] Capomolla S, Febo O, et al. Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day-hospital and usual care. J Am Coll Cardiol 2002; vol. 40, No. 7. [16] Kasper EK, Gerstenblith G, et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol 2002; vol. 39, No. 3. [17] Lusignan S, Wells S, et al. Compliance and effectiveness of 1 year s home telemonitoring. The report of a pilot study of patients with chronic heart failure. Eur J Heart Fail 2001; 3: [18] Ekman et al. Feasibility of a nurse-monitored, outpatient-care programme for elderly patients with moderated-to-severe, chronic heart failure. Eur Heart J 1998; vol 19: [19] Capomolla S, Pinna G, e tal. Heart failure case disease management program: a pilot study of home telemonitoring versus usual care. Eur Heart J Suppl 2004; 6: F91- F98. 10
11 [20] A. Stromberg, J. Martensson, et al. Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure. Eur Heart J 2003 ; 24 : [21] West J. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiolog 1997; 79:
12 Figure 1- Articles selection flowchart 12
13 Table 1 - Baseline studies' characteristics 13
14 Figure 2- meta-analysis 14
How should we treat atrial fibrillation in heart failure
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 23/24 Ottobre 2015 How should we treat atrial fibrillation in heart failure Matteo Anselmino Dipartimento Scienze Mediche Città
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationSuccessful Heart Failure Management Nurse/NP Run Clinics
Dagmar Knot RN BScN CCCN Transplant Coordination Team Leader Organ Transplant Center KFSHRC Riyadh, KSA Heart Failure Nurses Role, responsibilities & education Successful Heart Failure Management Nurse/NP
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationCongestive Heart Failure Management Program
Congestive Heart Failure Management Program The Congestive Heart Failure Program is the third statewide disease management program developed by CCNC. The clinical directors reviewed prevalence and outcome
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationKIH Cardiac Rehabilitation Program
KIH Cardiac Rehabilitation Program For any further information Contact: +92-51-2870361-3, 2271154 Feedback@kih.com.pk What is Cardiac Rehabilitation Cardiac rehabilitation describes all measures used to
More informationAtrial Fibrillation Cardiac rate control or rhythm control could be the key to AF therapy
Cardiac rate control or rhythm control could be the key to AF therapy Recent studies have proven that an option of pharmacologic and non-pharmacologic therapy is available to patients who suffer from AF.
More informationAtrial Fibrillation An update on diagnosis and management
Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationCloud Computing / Tele- Health in a Novel Integrated CHF Disease Management Program: The Israeli Experience
Cloud Computing / Tele- Health in a Novel Integrated CHF Disease Management Program: The Israeli Experience Haim Silber MD Programs Initiator Maccabi Health Care services and Gertner Institute, ISRAEL
More informationCONGESTIVE HEART FAILURE
abstract Heart failure is a serious illness characterized by impaired quality of life, decreased survival and frequent hospitalization, which mainly affects older adults. As the population ages, there
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationHOTLINE 1 O doente está primeiro! A Plataforma de Dados na Saúde e o Registo Nacional de Cardiologia de Intervenção.
HOTLINE 1 O doente está primeiro! A Plataforma de Dados na Saúde e o Registo Nacional de Cardiologia de Intervenção. Epidemiologia da doença cardíaca. O contributo dos registos observacionais. Carla Araújo
More informationNovember 15, 2013. Ann Laramee MS ANP-BC ACNS-BC CHFN FletcherAllen.org
Advance Care Planning with Heart Failure: Results of a Primary Care Practitioners Needs Survey 5 th Annual Nursing Research and Evidence Based Practice Symposium November 15, 2013 Ann Laramee MS ANP-BC
More informationTelemedicine in the Prevention and Monitoring of Heart Disease
Telemedicine in the Prevention and Monitoring of Heart Disease Prof. Dr. med. Friedrich Köhler 26. April 2012 Charité-Universitätsmedizin Berlin Facts Founded in 1710 11 Nobel laureates 12.922 employees
More informationAssessing the effectiveness of medical therapies finding the right research for each patient: Medical Evidence Matters
Title Assessing the effectiveness of medical therapies finding the right research for each patient: Medical Evidence Matters Presenter / author Roger Tritton Director, Product Management, Dialog (A ProQuest
More informationAlexandra Bargiota Assist. Prof. in Endocrinology University Hopsital of Larissa Thessaly, Greece. www.united4health.eu
Applying Evidence-Based Medicine with Telehealth the clinician view Assessing the impact of telehealth/telemedicine either via an RCT or an observational study the voice of a clinician Alexandra Bargiota
More informationProtocol. Cardiac Rehabilitation in the Outpatient Setting
Protocol Cardiac Rehabilitation in the Outpatient Setting (80308) Medical Benefit Effective Date: 07/01/14 Next Review Date: 09/15 Preauthorization No Review Dates: 07/07, 07/08, 05/09, 05/10, 05/11, 05/12,
More information1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA
1p36 and the Heart John Lynn Jefferies, MD, MPH, FACC, FAHA Director, Advanced Heart Failure and Cardiomyopathy Services Associate Professor, Pediatric Cardiology and Adult Cardiovascular Diseases Associate
More informationInnovation Platform: Sudden Cardiac Death
Innovation Platform: Sudden Cardiac Death Prof. dr. Bart Loeys CRC Antwerp General Assembly VzW Board of Directors Strategic Advisory Board Staff: 1 executive director 1 ICT manager 1 financial administration
More informationon behalf of the AUGMENT-HF Investigators
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
More informationBASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY
BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY American Osteopathic Association and the American College of Osteopathic Internists Specific Requirements For Osteopathic Subspecialty Training In Cardiology
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationNIHI Big Data in Healthcare Research Case Study
NIHI Big Data in Healthcare Research Case Study Professor Rob Doughty Heart Foundation Chair of Heart Health National Institute for Health Innovation and the Dept of Medicine, University of Auckland &
More informationEVIDENCE GRADING SYSTEM
I CSI INSTITUTE FOR CLINICAL SYSTEMS IMPROVEMENT EVIDENCE GRADING SYSTEM The evidence grading system used in ICSI guidelines and technology assessment reports is periodically reviewed and modified. The
More informationESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease
Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening
More informationATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)
ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation
More informationDIABETES: Applying Evidence- Based Medicine in Telehealth George E. Dafoulas MD, MBA in HSM, PhDc e- trikala SA, Greece
DIABETES: Applying Evidence- Based Medicine in Telehealth George E. Dafoulas MD, MBA in HSM, PhDc e- trikala SA, Greece www.united4health.eu Table of Contents Overview of current status and need for Evidence
More informationA randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation
A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation Gabriel Sayer Lay Abstract: Atrial fibrillation is a common form of irregular,
More informationClinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b
Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy Statement: Percutaneous
More informationGuide to Biostatistics
MedPage Tools Guide to Biostatistics Study Designs Here is a compilation of important epidemiologic and common biostatistical terms used in medical research. You can use it as a reference guide when reading
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationBarriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness
Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität
More informationAcquired, Drug-Induced Long QT Syndrome
Acquired, Drug-Induced Long QT Syndrome A Guide for Patients and Health Care Providers Sudden Arrhythmia Death Syndromes (SADS) Foundation 508 E. South Temple, Suite 202 Salt Lake City, Utah 84102 800-STOP
More informationTelecardiology Technical Innovations and Challegenes in Clinical Practice
Telecardiology Technical Innovations and Challegenes in Clinical Practice Axel Müller Clinic of Internal Medicine I (Head of Department: Prof. Dr. med. J. Schweizer) Klinikum Chemnitz ggmbh June 24, 2015
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationRunning head: COMMUNITY PROJECT 1. Community Project: Nurse Educator for Heart Failure Patients
Running head: COMMUNITY PROJECT 1 Community Project: Nurse Educator for Heart Failure Patients Isaac Agbettor, Anise Camacho, Nicole Hassna, Yesenia Hurtado, and Matthew Vega October 11, 2013 NURS 4410:
More informationHow to control atrial fibrillation in 2013 The ideal patient for a rate control strategy
How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy L. Pison, MD Advances in Cardiac Arrhythmias and Great Innovations in Cardiology - Torino, September 28 th 2013
More informationECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
More informationEssentia Health. Heart Failure and Remote Monitoring. Denise Buxbaum, RN, BSN, CHFN Heart Failure Program Manager
Essentia Health Heart Failure and Remote Monitoring Denise Buxbaum, RN, BSN, CHFN Heart Failure Program Manager Essentia Health Oct 2014 No reproduction without permission Why Heart Failure? Prevalence
More informationHow do you decide on rate versus rhythm control?
Heart Rhythm Congress 2014 How do you decide on rate versus rhythm control? Dr Ed Duncan Consultant Cardiologist & Electrophysiologist Define Rhythm Control DC Cardioversion Pharmacological AFFIRM study
More informationHeart Failure: Diagnosis and Treatment
Heart Failure: Diagnosis and Treatment Approximately 5 million people about 2 percent of the U.S. population are affected by heart failure. Diabetes affects 20.8 million Americans and 65 million Americans
More informationCARDIAC CARE. Giving you every advantage
CARDIAC CARE Giving you every advantage Getting to the heart of the matter The Cardiovascular Program at Northwest Hospital & Medical Center is dedicated to the management of cardiovascular disease. The
More informationHEALTH EVIDENCE REVIEW COMMISSION (HERC) COVERAGE GUIDANCE: DIAGNOSIS OF SLEEP APNEA IN ADULTS DATE: 5/9/2013 HERC COVERAGE GUIDANCE
HEALTH EVIDENCE REVIEW COMMISSION (HERC) COVERAGE GUIDANCE: DIAGNOSIS OF SLEEP APNEA IN ADULTS DATE: 5/9/2013 HERC COVERAGE GUIDANCE The following diagnostic tests for Obstructive Sleep Apnea (OSA) should
More informationCoronary Artery Disease leading cause of morbidity & mortality in industrialised nations.
INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.
More informationService delivery interventions
Service delivery interventions S A S H A S H E P P E R D D E P A R T M E N T O F P U B L I C H E A L T H, U N I V E R S I T Y O F O X F O R D CO- C O O R D I N A T I N G E D I T O R C O C H R A N E E P
More informationInpatient Heart Failure Management: Risks & Benefits
Inpatient Heart Failure Management: Risks & Benefits Dr. Kenneth L. Baughman Professor of Medicine Harvard Medical School Director, Advanced Heart Disease Section Brigham & Women's Hospital Harvard Medical
More informationVersion 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen
Version 1 2015 Module guide International Master Program Cardiovascular Science University of Göttingen Part 1 Theoretical modules Synopsis The Master program Cardiovascular Science contains four theoretical
More informationType II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease
Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University
More informationCOST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL
Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 19 23 (2007) COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL TRI MURTI ANDAYANI* AND IKE IMANINGSIH
More informationHow do you decide on rate versus rhythm control?
How do you decide on rate versus rhythm control? Dr. Mark O Neill Consultant Cardiologist & Electrophysiologist Assumptions Camm et al. EHJ 2010;Sept 25 epub Choice of strategy: Criteria for consideration
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Remit / Appraisal objective: Final scope To appraise the clinical and cost effectiveness of
More informationAtrial Fibrillation in the ICU: Attempting to defend 4 controversial statements
Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Salmaan Kanji, Pharm.D. The Ottawa Hospital The Ottawa Hospital Research Institute Conflict of Interest No financial, proprietary
More informationCENTRAL MONITORING AUTHORITY for CARDIOLOGY at EU LEVEL
Outline of Cardiology Training Chapter 6 Article 1 CENTRAL MONITORING AUTHORITY for CARDIOLOGY at EU LEVEL 1.1. The central monitoring authority for the specialty will be the European Board for the Specialty
More informationOutpatient/Ambulatory Rehab. Dedicated Trans-disciplinary Team (defined within Annotated References)
CARDIAC The delivery of Cardiac Rehab is unlike most other rehab populations. The vast majority of patients receive their rehab in outpatient or community settings and only a small subset requires an inpatient
More informationEfficacy and Tolerability of Antidepressant Duloxetine for Treatment of Hot Flushes in Menopausal Women
Efficacy and Tolerability of Antidepressant Duloxetine for Treatment of Hot Flushes in Menopausal Women Irina Shestakova, MD, PhD Research Center of Obstetrics, Gynecology and Perinatology Department of
More informationAtrial Fibrillation (AF) March, 2013
Atrial Fibrillation (AF) March, 2013 This handout is meant to help with discussions about the condition, and it is not a complete discussion of AF. We hope it will complement your appointment with one
More informationConcept Series Paper on Disease Management
Concept Series Paper on Disease Management Disease management is the concept of reducing health care costs and improving quality of life for individuals with chronic conditions by preventing or minimizing
More informationINHERIT. The Lancet Diabetes & Endocrinology In press
INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy a Randomized Intervention Trial with losartan Anna Axelsson, Kasper Iversen, Niels Vejlstrup, Carolyn
More informationTreatment of cardiogenic shock
ACUTE HEART FAILURE AND COMORBIDITY IN THE ELDERLY Treatment of cardiogenic shock Christian J. Wiedermann, M.D., F.A.C.P. Associate Professor of Internal Medicine, Medical University of Innsbruck, Austria
More informationAddendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter
22 July 2010 EMA/CHMP/EWP/213056/2010 Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter Draft Agreed by Efficacy Working Party July 2008 Adoption by CHMP for release
More informationCardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone
James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest
More informationThe new Heart Failure pathway
The new Heart Failure pathway An integrated and seamless Strategy Dr Sunil Balani Definition of Heart Failure The inability of the heart to pump blood at a rate commensurate with the requirements of metabolising
More informationEducational Goals & Objectives
Educational Goals & Objectives The Cardiology rotation will provide the resident with an understanding of cardiovascular physiology and its broad systemic manifestations. The resident will have the opportunity
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationCARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty
CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE Las Vegas, Nevada Bellagio March 4 6, 2016 Participating Faculty Friday, March 4th: 7:30 am - 8:00 am Registration and Hot Breakfast 8:00 am - 9:00 am Pulmonary
More informationAdvanced Heart Failure & Transplantation Fellowship Program
Advanced Heart Failure & Transplantation Fellowship Program Curriculum I. Patient Care When on the inpatient Heart Failure and Transplant Cardiology service, the cardiology fellow will hold primary responsibility
More informationFunctional Improvement for Heart Failure Patients After Left Ventricular Assistive Device Placement in a Free Standing Rehabilitation Hospital
Functional Improvement for Heart Failure Patients After Left Ventricular Assistive Device Placement in a Free Standing Rehabilitation Hospital Vittal R. Nagar, M.D, PhDc PGY II Mentor: Robert Nickerson,
More informationSummary Diagnosis and Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in People with Multiple Sclerosis (MS)
ETMIS 2012; Vol. 8: N o 7 Summary Diagnosis and Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in People with Multiple Sclerosis (MS) March 2012 A production of the Institut national d
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationTackling the Semantic Interoperability challenge
European Patient Summaries: What is next? Tackling the Semantic Interoperability challenge Dipak Kalra Cross-border health care The context for sharing health summaries Also useful for within-border health
More informationNP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
More informationLEVEL ONE MODULE EXAM PART ONE [Clinical Questions Literature Searching Types of Research Levels of Evidence Appraisal Scales Statistic Terminology]
1. What does the letter I correspond to in the PICO format? A. Interdisciplinary B. Interference C. Intersession D. Intervention 2. Which step of the evidence-based practice process incorporates clinical
More informationPopulation Health Management Program
Population Health Management Program Program (formerly Disease Management) is dedicated to improving our members health and quality of life. Our Population Health Management Programs aim to improve care
More informationgetemed Medizin- und Informationstechnik AG
getemed Medizin- und Informationstechnik AG Oderstraße 77 14513 Teltow Germany Ambulatory Monitoring of Physiological Parameters Robert Downes ehealth Conference, Berlin April 19, 2007 Contents Introduction
More informationADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE
I. PURPOSE To establish guidelines for the monitoring of antihypertensive therapy in adult patients and to define the roles and responsibilities of the collaborating clinical pharmacist and pharmacy resident.
More informationOsama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015
STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015 PROJECT TITLE: Analysis of ECG Exercise Stress Testing and Framingham Risk Score in Chest Pain Patients PRIMARY SUPERVISOR NAME: Dr. Edward Tan DEPARTMENT:
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
More informationManagement of Symptomatic Atrial Fibrillation
Management of Symptomatic Atrial Fibrillation John F. MacGregor, MD, FHRS Associate Medical Director, Cardiac Electrophysiology PeaceHealth St. Joseph Medical Center, Bellingham, WA September 18, 2015
More information4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts
Cardiac Rehabilitation: From the other side of the glass door No disclosures, no conflicts Charles X. Kim, MD, FACC, ABVM Objectives 1. Illustrate common CV benefits of CV rehab in real world practice.
More informationSuccess factors in Behavioral Medicine
Success factors in Behavioral Medicine interventions post myocardial infarction Depression Gunilla post myocardial Burell, PhD infarction Department of Public Health, Uppsala University, Sweden XIII Svenska
More informationAtrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology
Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of
More informationNational Medicines Information Centre
National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 www.nmic.ie THE CONTEMPORARY MANAGEMENT OF ATRIAL FIBRILLATION VOLUME 12 NUMBER 3 2006
More informationAfter acute myocardial infarction, diabetes CARDIAC OUTCOMES AFTER MYOCARDIAL INFARCTION IN ELDERLY PATIENTS WITH DIABETES MELLITUS
CARDIAC OUTCOMES AFTER MYOCARDIAL INFARCTION IN ELDERLY PATIENTS WITH DIABETES MELLITUS By Deborah Chyun, RN, PhD, Viola Vaccarino, MD, PhD, Jaime Murillo, MD, Lawrence H. Young, MD, and Harlan M. Krumholz,
More information6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology
Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die
More informationCOMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION
European Medicines Agency London, 19 July 2007 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR
More informationCritical appraisal of systematic reviews
Critical appraisal of systematic reviews Abalos E, Carroli G, Mackey ME, Bergel E Centro Rosarino de Estudios Perinatales, Rosario, Argentina INTRODUCTION In spite of the increasingly efficient ways to
More informationRandomized trials versus observational studies
Randomized trials versus observational studies The case of postmenopausal hormone therapy and heart disease Miguel Hernán Harvard School of Public Health www.hsph.harvard.edu/causal Joint work with James
More informationPreservation and Incorporation of Valuable Endoscopic Innovations (PIVI)
Preservation and Incorporation of Valuable Endoscopic Innovations (PIVI) The American Society for Gastrointestinal Endoscopy PIVI on Endoscopic Bariatric Procedures (short form) Please see related White
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationElectrocardiographic Issues in Williams Syndrome
Electrocardiographic Issues in Williams Syndrome R. Thomas Collins II, MD Assistant Professor, Pediatrics and Internal Medicine University of Arkansas for Medical Sciences Arkansas Children s Hospital
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:
More informationTransforming the patient experience with telehealth in Europe : "Applying Evidence-Based Medicine in Telehealth"
Transforming the patient experience with telehealth in Europe : "Applying Evidence-Based Medicine in Telehealth" George E. Dafoulas, MD, MBA in HSM, PhDc etrikala, Municipality of Trikala 5 th Regional
More informationTREATING ASPD IN THE COMMUNITY: FURTHERING THE PD OFFENDER STRATEGY. Jessica Yakeley Portman Clinic Tavistock and Portman NHS Foundation Trust
TREATING ASPD IN THE COMMUNITY: FURTHERING THE PD OFFENDER STRATEGY Jessica Yakeley Portman Clinic Tavistock and Portman NHS Foundation Trust Treating the untreatable? Lack of evidence base for ASPD Only
More informationINTRODUCTION TO EECP THERAPY
INTRODUCTION TO EECP THERAPY is an FDA cleared, Medicare approved, non-invasive medical therapy for the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and
More informationCritical Appraisal of Article on Therapy
Critical Appraisal of Article on Therapy What question did the study ask? Guide Are the results Valid 1. Was the assignment of patients to treatments randomized? And was the randomization list concealed?
More informationSECTION I: Request. SECTION II: Need. Program Description
SECTION I: Request This is a formal request for the Utah CARMA Center to be formally recognized by the University of Utah as a large, collaborative medical and academic center whose focus is on comprehensive
More information